Metabolic Health Blood Test UK: 10 Biomarkers That Reveal Whether Your Metabolism Is Working For or Against You

1. What is metabolic health?

Metabolic health describes how efficiently your body converts food into energy, stores it, and uses it. When the system works well, blood sugar stays stable, insulin is low, cholesterol is balanced, blood pressure is normal, and waist circumference is within range.

The clinical definition used in most research comes from the National Cholesterol Education Programme (NCEP ATP III) criteria. You are metabolically healthy if you meet all five without medication:

• Waist circumference: <94cm men, <80cm women (IDF threshold for European ethnicity)
• Fasting triglycerides: <1.7 mmol/L
• HDL cholesterol: >1.0 mmol/L men, >1.3 mmol/L women
• Blood pressure: <130/85 mmHg
• Fasting glucose: <5.6 mmol/L (or HbA1c <42 mmol/mol)

Fail even one criterion and you are metabolically unhealthy by definition. The 2018 study by Araújo et al. in Metabolic Syndrome and Related Disorders found that only 12.2% of American adults met all five criteria. UK data from the British Heart Foundation estimates that around 1 in 3 UK adults has metabolic syndrome (meeting three or more criteria), with prevalence rising sharply after age 40.

But these five criteria only capture the output of metabolic dysfunction. They miss the upstream drivers — insulin resistance, subclinical inflammation, liver fat accumulation, and hormonal disruption — that precede the measurable syndrome by years. A blood test that includes insulin, hs-CRP, and liver markers catches the process earlier.

2. Why your GP blood test misses metabolic dysfunction

When your GP orders a “general blood test,” you typically get an FBC, basic liver and kidney function, standard cholesterol (total, HDL, LDL), and sometimes HbA1c if diabetes is suspected. This tells you where you are on the disease spectrum, but nothing about where you are heading.

The critical gaps:

• Fasting insulin is almost never ordered in primary care — yet it's the earliest marker of insulin resistance, detectable 5-15 years before HbA1c rises
• Triglyceride-to-HDL ratio is not reported — the strongest lipid predictor of cardiovascular risk and insulin resistance
• hs-CRP is reserved for suspected infection or autoimmune disease — not used for metabolic inflammation screening
• ApoB is not routinely measured — yet it outperforms LDL for cardiovascular risk prediction (NICE CG181 acknowledges this but doesn't mandate testing)
• Liver enzymes are checked, but the interpretation stops at 'within range' — subclinical ALT elevation in the context of metabolic syndrome is usually ignored
• Vitamin D and magnesium are not included — both directly modulate insulin sensitivity

The result is that millions of people in the UK are told their blood tests are “fine” while insulin resistance, subclinical inflammation, and early fatty liver are already developing. The NHS pathway is designed to diagnose disease, not to detect the trajectory toward it.

3. The 10 biomarkers that matter

A comprehensive metabolic health panel should include these 10 markers, each testing a different facet of the system:

4. NHS ranges vs optimal ranges for metabolic health

NHS reference ranges define where 95% of the population falls. Optimal ranges define where metabolic risk is lowest based on prospective outcome data. The gap between “normal” and “optimal” is where preventable disease develops.

Sources: NICE NG28, NICE CG181, NICE NG49, AHA/ACC guidelines, ESC 2021 dyslipidaemia guidelines, SACN vitamin D report 2016, Diabetes Care meta-analyses. Optimal ranges reflect lowest-risk quartiles from prospective cohort studies.

5. Insulin resistance: the silent engine of metabolic disease

Insulin resistance is the upstream cause of most metabolic dysfunction. When cells become less responsive to insulin, the pancreas compensates by producing more. Blood sugar stays normal for years while insulin climbs. This is why HbA1c alone is a dangerously late indicator.

The progression follows a predictable sequence documented in a landmark 2009 study in Diabetes Care by Tabák et al.:

1. 1.

   Compensated resistance (5–15 years before diagnosis)

   Fasting insulin elevated, HbA1c normal, triglycerides rising. No symptoms. GP says 'everything is fine.'

2. 2.

   Early decompensation (2–5 years before diagnosis)

   HbA1c enters pre-diabetic range (42–47 mmol/mol). Triglycerides elevated. HDL falling. Weight gain accelerating, especially visceral. ALT may be mildly elevated.

3. 3.

   Beta-cell failure

   Pancreatic beta cells can no longer compensate. HbA1c crosses 48 mmol/mol. Type 2 diabetes diagnosed. But by this point, an estimated 50% of beta-cell function has been lost.

The critical insight: testing fasting insulin catches the problem at Stage 1, when it is fully reversible through lifestyle change alone. The Diabetes Prevention Programme (DPP) trial published in the New England Journal of Medicine (2002) demonstrated that lifestyle intervention reduced progression to diabetes by 58% — more effective than metformin (31%).

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated from fasting glucose and fasting insulin. A HOMA-IR below 1.0 indicates excellent insulin sensitivity. Between 1.0 and 2.0 suggests early resistance. Above 2.5 is consistent with significant metabolic dysfunction. This single calculation is more informative than an HbA1c result for early detection.

6. The triglyceride-to-HDL ratio: a hidden metabolic signal

Standard lipid panels report total cholesterol, HDL, LDL, and triglycerides separately. But the ratio of triglycerides to HDL (TG:HDL) is a stronger predictor of insulin resistance and cardiovascular risk than any individual number.

Research published in Circulation (2008) found that the TG:HDL ratio was the strongest lipid predictor of coronary heart disease — superior to LDL cholesterol. In metabolic terms, a high ratio reflects insulin-driven overproduction of VLDL particles and CETP-mediated depletion of HDL.

Your GP report will not calculate this ratio for you. But if your triglycerides are 1.8 and your HDL is 1.1, your TG:HDL is 1.64 — technically “normal” on each individual measure but firmly in the moderate-risk band when combined.

7. Your liver is a metabolic organ

Non-alcoholic fatty liver disease (NAFLD) — now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD) — affects an estimated 25–30% of UK adults. It is the hepatic manifestation of insulin resistance: when cells resist insulin, the liver converts excess glucose to fat and stores it in hepatocytes.

The progression from simple steatosis to steatohepatitis (NASH) to fibrosis to cirrhosis is well-documented, but the early stages are entirely asymptomatic. ALT is the most accessible screening marker. Research in the BMJ (2020) found that ALT above the “normal” upper limit was associated with a 5× increase in liver-related mortality — but also with a 2× increase in cardiovascular mortality, because the metabolic dysfunction driving liver fat also drives arterial disease.

The NICE NG49 guideline on NAFLD assessment recommends ELF (Enhanced Liver Fibrosis) or FIB-4 scoring for anyone with suspected fatty liver. But the problem starts earlier: a GP seeing ALT of 35 IU/L in a male patient will report it as “within range” (NHS upper limit ~50 IU/L), even though updated evidence suggests the optimal cutoff for liver health is 25 IU/L for men and 19 IU/L for women.

When elevated ALT appears alongside high triglycerides, low HDL, and elevated fasting insulin, it is very likely reflecting metabolic fatty liver — and that combination demands lifestyle intervention, not a repeat test in 6 months.

8. Five metabolic result patterns we see

Metabolic results rarely exist in isolation. These are the five most common patterns, from earliest to most advanced:

9. Which Helvy panel covers what

Not every panel tests every metabolic marker. Here's how the 10 metabolic biomarkers map to our panels:

The Performance panel covers all 10 metabolic markers. If you specifically want the full metabolic picture including fasting insulin and HOMA-IR, it is the most comprehensive option. The Heart panel covers the cardiovascular metabolic markers (lipids + HbA1c + hs-CRP + ApoB) but not insulin or liver function. The Essential panel covers the baseline markers at the lowest price point.

10. Evidence-based interventions ranked by effect size

If your metabolic markers are suboptimal, these are the interventions with the strongest evidence base, ranked by magnitude of effect on insulin sensitivity and metabolic markers:

The consistent finding across all high-quality trials is that lifestyle intervention outperforms medication for metabolic syndrome reversal when started early. The DPP trial remains the gold standard: structured lifestyle change (diet + exercise + weight loss) reduced diabetes incidence by 58%, compared to 31% for metformin. But this only works when you know where you stand — which requires testing the right markers.

11. When and how to test

Who should get a metabolic health blood test?

• You are over 35 and have never had fasting insulin tested
• You carry excess weight around your midsection (visceral fat)
• You have a family history of type 2 diabetes, heart disease, or fatty liver
• Your energy crashes after meals or you experience afternoon fatigue
• You have been told your cholesterol is 'borderline' or 'a bit high'
• You have PCOS, which is strongly associated with insulin resistance
• You are on a GLP-1 agonist (Ozempic, Wegovy, Mounjaro) and want to track metabolic improvement
• You want a baseline before making dietary or exercise changes

Testing protocol

• Fast for 12 hours overnight — essential for accurate insulin, glucose, and triglyceride readings
• Water only during the fast — black coffee is acceptable but may affect cortisol if included in your panel
• Test in the morning, before 10am — insulin follows a diurnal pattern and is most stable in the early morning
• Avoid intense exercise for 24 hours — acute exercise transiently improves insulin sensitivity, which would mask chronic resistance
• Take medications as normal unless your GP advises otherwise — statins, metformin, and thyroid medication should not be skipped for testing
• Avoid alcohol for 48 hours — even moderate alcohol temporarily affects liver enzymes and triglycerides

How often to retest

12. GP vs Helvy for metabolic testing

The NHS is excellent at diagnosing metabolic disease. It is not designed for metabolic optimisation. If your goal is to catch insulin resistance before it becomes diabetes, track your metabolic trajectory over time, and know your HOMA-IR, TG:HDL ratio, and ApoB — private testing fills the gap that primary care cannot.

13. Frequently asked questions